Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.41 |
| ▸ | KDM1A | O60341 | 9/20 | 0.38 |
| ▸ | MAOA | P21397 | 8/20 | 0.38 |
| ▸ | MAOB | P27338 | 8/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151922 | 0.97 | CHRM2 (0.43) | CHRM2CHRM4CHRM1CHRM3SIGMAR1 | |
| SCHEMBL1151862 | 0.91 | CHRM2 (0.38) | CHRM2CHRM4CHRM1CHRM3SIGMAR1 | |
| SCHEMBL9100498 | 0.90 | CHRM2 (0.50) | CHRM2CHRM4CHRM1CHRM3SIGMAR1 | |
| SCHEMBL9859831 | 0.81 | OPRM1 (0.44) | CHRM2CHRM4CHRM1CHRM3SIGMAR1 | |
| SCHEMBL11205408 | 0.78 | ESRRG (0.57) | ESR1 | |
| SCHEMBL11205406 | 0.78 | ESRRG (0.57) | ESR1 | |
| SCHEMBL27575556 | 0.75 | KDM1A (0.43) | CHRM2CHRM4CHRM1CHRM3SIGMAR1 | |
| SCHEMBL9098140 | 0.73 | CHRM2 (0.48) | CHRM2CHRM4CHRM1CHRM3SIGMAR1 | |
| SCHEMBL1151545 | 0.71 | CYP2D6 (0.47) | CHRM2CHRM4CHRM1CHRM3SIGMAR1 | |
| SCHEMBL16335287 | 0.71 | CHRM2 (0.51) | CHRM2CHRM4CHRM1CHRM3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | claimed |
| EP-0095875-A2 | Novel tri-phenyl alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-12-07 | — | — | EP | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2008133884-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-11-06 | — | — | WO | disclosed |
| US-4996225-A | Antitumor agents | FARMOS GROUP LTD. (FI) | 1991-02-26 | — | — | US | disclosed |
| US-4696949-A | ANTITUMOR AGENTS, ANTIESTROGENS | FARMOS GROUP LTD. (FI) | 1987-09-29 | — | — | US | disclosed |
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | disclosed |
| EP-0095875-A2 | Novel tri-phenyl alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CHRM2 4828/4885CHRM4 4806/4885CHRM1 4858/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CHRM2 4828/4885CHRM4 4806/4885CHRM1 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.